2023
Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing
Marczyk M, Fu C, Lau R, Du L, Trevarton A, Sinn B, Gould R, Pusztai L, Hatzis C, Symmans W. Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing. Cancer Cytopathology 2023, 131: 289-299. PMID: 36650408, PMCID: PMC10614161, DOI: 10.1002/cncy.22679.Peer-Reviewed Original ResearchConceptsCytology smearsBreast cancerConcordance correlation coefficientTumor tissue samplesParaffin-embedded sectionsClinical diagnostic proceduresSurgical resectionRNA sequencingTumor stromaCytologic specimensDiagnostic proceduresLin's concordance correlation coefficientPapanicolaou stainCancerTissue samplesDNA mutation testingSmearsSimilar concordanceTranscriptome RNA-SeqDiagnostic cytologyAllele fractionExpression levelsRNA-seqExpression of genesGene expression levels
2022
Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
Marczyk M, Mrukwa A, Yau C, Wolf D, Chen Y, Balassanian R, Nanda R, Parker B, Krings G, Sattar H, Zeck J, Albain K, Boughey J, Liu M, Elias A, Clark A, Venters S, Shad S, Basu A, Asare S, Buxton M, Asare A, Rugo H, Perlmutter J, DeMichele A, Yee D, Berry D, Veer L, Symmans W, Esserman L, Pusztai L, Consortium I. Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Annals Of Oncology 2022, 33: 814-823. PMID: 35513244, DOI: 10.1016/j.annonc.2022.04.072.Peer-Reviewed Original ResearchConceptsTrial armsExperimental armSurvival differencesExact testPathologic complete response rateClinical trial armsI-SPY2 trialNeoadjuvant chemotherapy efficacyComplete response rateBreast cancer trialsCytotoxic efficacyFisher's exact testImpact of treatmentNeoadjuvant chemotherapyPCR ratePathologic responseResidual cancerControl cohortCancer trialsAssessed associationsChemotherapy efficacyEarly surrogateOlaparib armResponse rateHigher cytotoxic efficacyPredictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.Peer-Reviewed Original ResearchConceptsBasal-like triple-negative breast cancerPathologic complete responseResidual diseaseNeoadjuvant durvalumabDNA damage repairSomatic mutationsBreast cancerWnt/β-cateninHigh expressionTriple-negative breast cancerBasal-Like TripleDoxorubicin/cyclophosphamideDNA repairTumor mutation burdenRNA sequencingEpithelial-mesenchymal transitionFive-gene signatureB-cell markersCancer driversEnrichment analysisNegative breast cancerDamage repairGene expressionJAK-STATCell cycleComprehensive Analysis of Metabolic Isozyme Targets in Cancer
Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research 2022, 82: 1698-1711. PMID: 35247885, PMCID: PMC10883296, DOI: 10.1158/0008-5472.can-21-3983.Peer-Reviewed Original ResearchConceptsPotential therapeutic targetAcetyl-CoA carboxylase 1Therapeutic targetCancer typesCell linesBreast cancer viabilityPatient-derived xenograftsNovel metabolic targetsCorresponding cell linesExpression patternsDrug treatmentMatching normal tissuesRelated commentaryTumor growthMalignant transformationSmall molecule inhibitionCancer viabilityCancer Cell Line EncyclopediaNormal tissuesMetabolic vulnerabilitiesCarboxylase 1Anticancer therapyCellular changesCell proliferationMetabolic reprogramming
2021
Analysis of the Applicability of microRNAs in Peripheral Blood Leukocytes as Biomarkers of Sensitivity and Exposure to Fractionated Radiotherapy towards Breast Cancer
Marczyk M, Polańska J, Wojcik A, Lundholm L. Analysis of the Applicability of microRNAs in Peripheral Blood Leukocytes as Biomarkers of Sensitivity and Exposure to Fractionated Radiotherapy towards Breast Cancer. International Journal Of Molecular Sciences 2021, 22: 8705. PMID: 34445424, PMCID: PMC8395710, DOI: 10.3390/ijms22168705.Peer-Reviewed Original ResearchConceptsBreast cancer patientsExternal beam radiotherapyCourse of radiotherapyPeripheral blood leukocytesBiomarkers of sensitivityLogistic regression modelsMultinomial logistic regression modelsFractionated RadiotherapyInter-individual variabilityCancer patientsUnivariate analysisBreast cancerCombination of miRNAsBeam radiotherapyBlood leukocytesBlood samplesPromising biomarkerTotal doseSensitive biomarkerRadiotherapyPatientsStrong inter-individual variabilityBiomarkersDoseLeukocytes
2019
The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues
Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Pusztai L, Hatzis C, Symmans WF. The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues. BMC Cancer 2019, 19: 1189. PMID: 31805884, PMCID: PMC6896723, DOI: 10.1186/s12885-019-6363-0.Peer-Reviewed Original ResearchConceptsBreast cancerFresh frozenParaffin-embedded tumor samplesFF samplesFFPE samplesConcordance correlation coefficientMixed-effects model analysisBreast cancer signaturesQiagen RNeasy kitWhole transcriptome RNA sequencingParaffin-embedded tissuesTranscriptome RNA sequencingLinear mixed-effects model analysisGene expression signaturesDifferent kitsClinical trialsGene signatureTumor samplesGene expressionTranslational researchCancerTissue samplesExpression signaturesArchival formalinSimilar concordanceLung cancer survival and comorbidities in lung cancer screening participants of the Gdańsk screening cohort
Ostrowski M, Marczyk M, Dziedzic R, Jelitto-Górska M, Marjański T, Pisiak S, Jędrzejczyk T, Polańska J, Zdrojewski T, Wojtyniak B, Rzyman W. Lung cancer survival and comorbidities in lung cancer screening participants of the Gdańsk screening cohort. European Journal Of Public Health 2019, 29: 1114-1117. PMID: 31004154, DOI: 10.1093/eurpub/ckz052.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseLung cancer screening programsCancer screening programsCardiovascular diseaseDiabetes mellitusLung cancerScreening programLung cancer detection rateMedical eventsModifiable risk factorsLung cancer survivalObstructive pulmonary diseaseLung cancer patientsCancer detection rateHealth care providersHealth care systemWorld Health OrganizationScreening groupHeavy smokersPulmonary diseaseScreening cohortCancer patientsCancer survivalRisk factorsCare providersDefining Risk of Late Recurrence in Early-Stage Estrogen Receptor–Positive Breast Cancer: Clinical Versus Molecular Tools
Foldi J, O'Meara T, Marczyk M, Sanft T, Silber A, Pusztai L. Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor–Positive Breast Cancer: Clinical Versus Molecular Tools. Journal Of Clinical Oncology 2019, 37: jco.18.01933. PMID: 30943126, DOI: 10.1200/jco.18.01933.Peer-Reviewed Original Research
2017
Serum lipid profile discriminates patients with early lung cancer from healthy controls
Ros-Mazurczyk M, Jelonek K, Marczyk M, Binczyk F, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P. Serum lipid profile discriminates patients with early lung cancer from healthy controls. Lung Cancer 2017, 112: 69-74. PMID: 29191603, DOI: 10.1016/j.lungcan.2017.07.036.Peer-Reviewed Original ResearchConceptsEarly lung cancerSerum lipid profileLung cancerNegative predictive valuePredictive valueCancer patientsLipid profileComputed tomography lung cancer screeningLow-dose computed tomography (LDCT) lung cancer screeningTomography lung cancer screeningEarly-stage lung cancerHealthy participantsEarly lung cancer patientsLow-dose computed tomographyHigh-risk smokersLung cancer screeningLung cancer patientsStage lung cancerMaximum negative predictive valueBlood-based biomarkersPositive predictive valueSerum lipidomeCancer screeningHealthy controlsSerum signatureStage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry†
Dziedzic R, Żurek W, Marjański T, Rudziński P, Orłowski TM, Sawicka W, Marczyk M, Polańska J, Rzyman W. Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry†. European Journal Of Cardio-Thoracic Surgery 2017, 52: 363-369. PMID: 28402455, DOI: 10.1093/ejcts/ezx092.Peer-Reviewed Original ResearchConceptsStage I NSCLCLung Cancer RegistryWedge resectionCell lung cancerOverall survivalSurvival rateCancer RegistryLung cancerCox proportional hazard ratiosPropensity score-matched analysisProportional hazard ratiosGroup of patientsTreatment of patientsLong-term resultsMethod of resectionLobar resectionHazard ratioSublobar resectionMediastinal lymphadenectomySurgical treatmentPatient groupRetrospective analysisSegmentectomyLobectomyStudy group
2016
Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer
Bobowicz M, Skrzypski M, Czapiewski P, Marczyk M, Maciejewska A, Jankowski M, Szulgo-Paczkowska A, Zegarski W, Pawłowski R, Polańska J, Biernat W, Jaśkiewicz J, Jassem J. Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer. Clinical & Experimental Metastasis 2016, 33: 765-773. PMID: 27485175, PMCID: PMC5110606, DOI: 10.1007/s10585-016-9810-1.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalColon cancerMMR statusShorter distant metastasis-free survivalEarly-stage colon cancerMiR-592 expressionGroup of patientsMetastasis-free survivalExpression signaturesCox univariate analysisStage colon cancerNormal colon mucosa samplesColon mucosa samplesMiRNA expression signaturesAdjuvant chemotherapyDistant relapseMiRNA expressionDistant metastasisMiR-423-5pCC patientsPrognostic significancePrognostic valueSuch therapyUnivariate analysisHigh riskSerum mass profile signature as a biomarker of early lung cancer
Widlak P, Pietrowska M, Polanska J, Marczyk M, Ros-Mazurczyk M, Dziadziuszko R, Jassem J, Rzyman W. Serum mass profile signature as a biomarker of early lung cancer. Lung Cancer 2016, 99: 46-52. PMID: 27565913, DOI: 10.1016/j.lungcan.2016.06.011.Peer-Reviewed Original ResearchConceptsEarly lung cancerLung cancerNegative predictive valuePredictive valueComputed tomographyEarly-stage lung cancerLow-dose computed tomographyIndeterminate pulmonary nodulesStage lung cancerPotential clinical usefulnessPositive predictive valueValidation cohortHealthy controlsClinical usefulnessDiscovery cohortBlood samplesIndependent cohortWeight serum fractionsPulmonary nodulesIndependent sample setCancerPatientsHealthy participantsMolecular biomarkersCohort
2015
Influence of genetic background and oxidative stress response on risk of mandibular osteoradionecrosis after radiotherapy of head and neck cancer
Danielsson D, Brehwens K, Halle M, Marczyk M, Sollazzo A, Polanska J, Munck-Wikland E, Wojcik A, Haghdoost S. Influence of genetic background and oxidative stress response on risk of mandibular osteoradionecrosis after radiotherapy of head and neck cancer. Head & Neck 2015, 38: 387-393. PMID: 25352150, DOI: 10.1002/hed.23903.Peer-Reviewed Original ResearchConceptsRadiotherapy of headGlutathione S-transferase P1Mandibular osteoradionecrosisNeck cancerCohort of patientsIndividual radiosensitivitySingle nucleotide polymorphismsRadiation-induced oxidative stressDihydro-2'-deoxyguanosine levelsNeck radiotherapy treatmentConcomitant brachytherapyOxidative stress responseSevere complicationsPatient cohortOsteoradionecrosisSNP rs1695Multivariate analysisTissue damageHealthy tissue damagePatientsOxidative stressRadiotherapy treatmentRadiotherapyCohortBiomarker analysis
2014
Radiation-induced Changes in Levels of Selected Proteins in Peripheral Blood Serum of Breast Cancer Patients as a Potential Triage Biodosimeter for Large-scale Radiological Emergencies
Deperas-Kaminska M, Bajinskis A, Marczyk M, Polanska J, Wersäll P, Lidbrink E, Ainsbury EA, Guipaud O, Benderitter M, Haghdoost S, Wojcik A. Radiation-induced Changes in Levels of Selected Proteins in Peripheral Blood Serum of Breast Cancer Patients as a Potential Triage Biodosimeter for Large-scale Radiological Emergencies. Health Physics 2014, 107: 555-563. PMID: 25353241, DOI: 10.1097/hp.0000000000000158.Peer-Reviewed Original ResearchConceptsPeripheral blood serumBreast cancer patientsLarge-scale radiological emergencyCancer patientsApolipoprotein EConsistent dose-response relationshipBlood serumExternal beam radiotherapyIrradiation of skinKinase 4Dose-response relationshipLogistic regression modelsPartial-body exposuresPurpose of triageMultinomial logistic regression modelsBeam radiotherapyBlood samplesFetuin BMultivariate analysisBody exposureDifferent dosesRadiation-induced changesSerumProtein 7Factor X
2011
Radiation-related Changes in Serum Proteome Profiles Detected by Mass Spectrometry in Blood of Patients Treated with Radiotherapy Due to Larynx Cancer
WIDŁAK P, PIETROWSKA M, WOJTKIEWICZ K, RUTKOWSKI T, WYGODA A, MARCZAK Ł, MARCZYK M, POLAŃSKA J, WALASZCZYK A, DOMIŃCZYK I, SKŁADOWSKI K, STOBIECKI M, POLAŃSKI A. Radiation-related Changes in Serum Proteome Profiles Detected by Mass Spectrometry in Blood of Patients Treated with Radiotherapy Due to Larynx Cancer. Journal Of Radiation Research 2011, 52: 575-581. PMID: 21768750, DOI: 10.1269/jrr.11019.Peer-Reviewed Original ResearchConceptsMass spectrometrySerum samplesLarynx cancerTotal dosesSerum proteomeEnd of radiotherapyStart of radiotherapyRadiation-related changesBlood of patientsConsecutive blood samplesSerum proteome profilesMALDI-TOF mass spectrometryEarly time pointsHuman serum proteomeRadical radiotherapyPeptide ionsBlood samplesPatientsProteome profilesFinal irradiationRetrospective markerPilot studyRadiotherapyTime pointsAnalysed groupAssociation between plasma proteome profiles analysed by mass spectrometry, a lymphocyte-based DNA-break repair assay and radiotherapy-induced acute mucosal reaction in head and neck cancer patients
Pietrowska M, Polańska J, Walaszczyk A, Wygoda A, Rutkowski T, Składowski K, Marczak Ł, Stobiecki M, Marczyk M, Polański A, Widłak P. Association between plasma proteome profiles analysed by mass spectrometry, a lymphocyte-based DNA-break repair assay and radiotherapy-induced acute mucosal reaction in head and neck cancer patients. International Journal Of Radiation Biology 2011, 87: 711-719. PMID: 21351848, DOI: 10.3109/09553002.2011.556174.Peer-Reviewed Original ResearchConceptsAcute mucosal reactionsAcute reactionsMucosal reactionsNeck cancerPlasma proteomeNeck cancer patientsPlasma proteome profilesDefinitive radiotherapyCancer patientsPredictive markerHealthy donorsBlood samplesHealthy individualsPatientsRadiotherapyPlasma samplesComet assayLymphocytesCancerMaximal intensityMarkersProteome profiles